These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 31636564)

  • 1. Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms.
    Lee NY; Ko WC; Hsueh PR
    Front Pharmacol; 2019; 10():1153. PubMed ID: 31636564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cracking the Challenge of Antimicrobial Drug Resistance with CRISPR/Cas9, Nanotechnology and Other Strategies in ESKAPE Pathogens.
    Zohra T; Numan M; Ikram A; Salman M; Khan T; Din M; Salman M; Farooq A; Amir A; Ali M
    Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens.
    Santajit S; Indrawattana N
    Biomed Res Int; 2016; 2016():2475067. PubMed ID: 27274985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternatives for the treatment of infections caused by ESKAPE pathogens.
    da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R
    J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review.
    Mulani MS; Kamble EE; Kumkar SN; Tawre MS; Pardesi KR
    Front Microbiol; 2019; 10():539. PubMed ID: 30988669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial Activity of Two Different Types of Silver Nanoparticles against Wide Range of Pathogenic Bacteria.
    Holubnycha V; Husak Y; Korniienko V; Bolshanina S; Tveresovska O; Myronov P; Holubnycha M; Butsyk A; Borén T; Banasiuk R; Ramanavicius A; Pogorielov M
    Nanomaterials (Basel); 2024 Jan; 14(2):. PubMed ID: 38251102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying the Evolutionary Conservation of Genes Encoding Multidrug Efflux Pumps in the ESKAPE Pathogens To Identify Antimicrobial Drug Targets.
    Brooks LE; Ul-Hasan S; Chan BK; Sistrom MJ
    mSystems; 2018; 3(3):. PubMed ID: 29719870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metal Nanoparticle-Based Biosensors for the Early Diagnosis of Infectious Diseases Caused by ESKAPE Pathogens in the Fight against the Antimicrobial-Resistance Crisis.
    Gutiérrez-Santana JC; Rosas-Espinosa V; Martinez E; Casiano-García E; Coria-Jiménez VR
    Biosensors (Basel); 2024 Jul; 14(7):. PubMed ID: 39056615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kisameet Clay Exhibits Potent Antibacterial Activity against the ESKAPE Pathogens.
    Behroozian S; Svensson SL; Davies J
    mBio; 2016 Jan; 7(1):e01842-15. PubMed ID: 26814180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antimicrobial agents for combating antibiotic-resistant bacteria.
    Chang RYK; Nang SC; Chan HK; Li J
    Adv Drug Deliv Rev; 2022 Aug; 187():114378. PubMed ID: 35671882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coping with the ESKAPE pathogens: Evolving strategies, challenges and future prospects.
    Aloke C; Achilonu I
    Microb Pathog; 2023 Feb; 175():105963. PubMed ID: 36584930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans.
    El Haddad L; Harb CP; Gebara MA; Stibich MA; Chemaly RF
    Clin Infect Dis; 2019 Jun; 69(1):167-178. PubMed ID: 30395179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections.
    Jiang L; Lin J; Taggart CC; Bengoechea JA; Scott CJ
    J Interdiscip Nanomed; 2018 Sep; 3(3):111-121. PubMed ID: 30443410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESKAPE in China: epidemiology and characteristics of antibiotic resistance.
    Luo Q; Lu P; Chen Y; Shen P; Zheng B; Ji J; Ying C; Liu Z; Xiao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2317915. PubMed ID: 38356197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterial Antibiotic Resistance: The Most Critical Pathogens.
    Mancuso G; Midiri A; Gerace E; Biondo C
    Pathogens; 2021 Oct; 10(10):. PubMed ID: 34684258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds.
    Jadimurthy R; Mayegowda SB; Nayak SC; Mohan CD; Rangappa KS
    Biotechnol Rep (Amst); 2022 Jun; 34():e00728. PubMed ID: 35686013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.
    Ma YX; Wang CY; Li YY; Li J; Wan QQ; Chen JH; Tay FR; Niu LN
    Adv Sci (Weinh); 2020 Jan; 7(1):1901872. PubMed ID: 31921562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial.
    Giammanco A; Calà C; Fasciana T; Dowzicky MJ
    mSphere; 2017; 2(1):. PubMed ID: 28124025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in the Use of Molecular Methods for the Diagnosis of Bacterial Infections.
    Gerace E; Mancuso G; Midiri A; Poidomani S; Zummo S; Biondo C
    Pathogens; 2022 Jun; 11(6):. PubMed ID: 35745518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Resistance in
    Lupo A; Haenni M; Madec JY
    Microbiol Spectr; 2018 Jun; 6(3):. PubMed ID: 30101740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.